UDD Logo
CRIS - Current Research Information System
New user? Click here to register.Have you forgotten your password?
Communities & Collections
Research Outputs
Fundings & Projects
Researchers
Datasets
Statistics
  1. Home
  2. CRIS
  3. Publications
  4. Pharmacogenetics in Psychiatry: Perceived Value and Opinions in a Chilean Sample of Practitioners
Details

Pharmacogenetics in Psychiatry: Perceived Value and Opinions in a Chilean Sample of Practitioners

Journal
Frontiers in Pharmacology
ISSN
1663-9812
Date Issued
2021
Author(s)
UNDURRAGA FOURCADE, JUAN PABLO  
Facultad de Medicina Clínica Alemana Universidad del Desarrollo  
Ignacio Bórquez-Infante
Nicolás A. Crossley
Miguel L. Prieto
REPETTO LISBOA, MARIA GABRIELA  
Facultad de Medicina Clínica Alemana Universidad del Desarrollo  
Type
Resource Types::text::journal::journal article
Scopus ID
2-s2.0-85104958889
WoS ID
WOS:000645277500001
DOI
10.3389/fphar.2021.657985
URL
https://investigadores.udd.cl/handle/123456789/6491
URL Institutional Repository
http://hdl.handle.net/11447/5816
Abstract
<jats:p>Use of pharmacogenetics (PGx) testing to guide clinical decisions is growing in developed countries. Published guidelines for gene–drug pair analysis are available for prescriptions in psychiatry, but information on their utilization, barriers, and health outcomes in Latin America is limited. As a result, this work aimed at exploring current use, opinions, and perceived obstacles on PGx testing among psychiatrists in Chile, via an online, anonymous survey. Among 123 respondents (5.9% of registered psychiatrists in the country), 16.3% reported ever requesting a PGx test. The vast majority (95%) of tests were ordered by clinicians practicing in the Metropolitan Region of Santiago. Having more than 20 years in practice was positively associated with prior use of PGx (p 0.02, OR 3.74 (1.19–11.80)), while working in the public health system was negatively associated (OR 0.30 (0.10–0.83)). Perceived barriers to local implementation included insufficient evidence of clinical utility, limited clinicians’ knowledge on PGx and on test availability, and health systems’ issues, such as costs and reimbursement. Despite the recognition of these barriers, 80% of respondents asserted that it is likely that they will incorporate PGx tests in their practice in the next five years. Given these results, we propose next steps to facilitate implementation such as further research in health outcomes and clinical utility of known and novel clinically actionable variants, growth in local sequencing capabilities, education of clinicians, incorporation of clinical decision support tools, and economic evaluations, all in local context.</jats:p>
Cite this document
Undurraga, J., Bórquez-Infante, I., Crossley, N. A., Prieto, M. L., & Repetto, G. M. (2021). Pharmacogenetics in psychiatry: Perceived value and opinions in a chilean sample of practitioners. Frontiers in Pharmacology, 12, 657985. https://doi.org/10.3389/fphar.2021.657985
Project(s)
Prodromal manifestations of Parkinson´s disease in a high-risk population: 22q11.2 microdeletion syndrome  
Development of novel imaging techniques to study the brain in severe mental health disorders  
Subjects
pharmacogenetics

; 

psychiatry

; 

implementation

; 

chile

; 

latin america

; 

article

; 

chilean

; 

clinical decision support system

; 

clinical practice

; 

economic evaluation

; 

health care cost

; 

health care system

; 

human

; 

pharmacogenetic testing

; 

pharmacogenetics

; 

professional knowledge

; 

psychiatrist

; 

psychiatry

; 

public health

; 

reimbursement
Logo Universidad de Desarrollo
Encuéntranos en:

Sede Santiago

Av. Plaza 680, Las Condes

Contacto|Mapa

Sede Concepción

Ainavillo 456, Concepción

Contacto|Mapa

Hosting & SupportLogo Scimago Lab

Built with DSpace-CRIS software - Extension maintained and optimized by 4science

  • Accessibility settings
  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify